The first mass-market cell therapy?

Aurion Biotech, a US regenerative medicine firm, is developing a cell therapy to restore vision for people with corneal endothelial disease. The therapy, AURN001, is the first allogeneic cell therapy candidate that could potentially scale to serve millions of patients. The FDA has granted the therapy BTD and RMAT designations, and Aurion recently completed enrollment for a phase 1/2 trial in the US and Canada.